Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) Benefiting From a Molecular Test on the Hospital Platforms of Molecular Genetics.
NCT number | NCT01700582 |
Other study ID # | Biomarkers-France |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 2012 |
Est. completion date | April 2013 |
Verified date | July 2023 |
Source | Intergroupe Francophone de Cancerologie Thoracique |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).
Status | Completed |
Enrollment | 17664 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Advanced Non-small cell lung cancer (NSLC) - Biomarkers analysis on hospital platforms Exclusion Criteria: - Histology other than NSLC |
Country | Name | City | State |
---|---|---|---|
France | Clinique Calabet - Centre de Radiothérapie et d'Oncologie | Agen | |
France | Clinique Claude Bernard | Albi | |
France | Clinique de l'Europe | Amiens | |
France | CHU d'Angers | Angers | |
France | Hôpital Privé d'Antony | Antony | |
France | CHIC | Aulnay-Sous-Bois | |
France | Auxerre - CH | Auxerre | |
France | CH d'Avignon | Avignon | |
France | CH de la Côte Basque | Bayonne | |
France | CHU Besancon - Pneumologie | Besancon | |
France | CH de Béziers | Béziers | |
France | Blois - CH | Blois | |
France | CHU Avicenne | Bobigny | |
France | Hôpital Ambroise Paré - Pneumologie | Boulogne | |
France | Hôpital Fleyriat | Bourg en Bresse | |
France | Hôpital de Briançon | Briançon | |
France | CHU Côte de Nâcre | Caen | |
France | Cahors - CH | Cahors | |
France | CH de Cannes | Cannes | |
France | Chambray Les Tours - Clinique Léonard de Vinci | Chambray Les Tours | |
France | CH de Chartres Hôpital Louis Pasteur | Chartres | |
France | Chevilly-Larue - CH | Chevilly-Larue | |
France | Hôpital de Cholet - Pneumologie | Cholet | |
France | Hôpital Percy-Armées - Pneumologie | Clamart | |
France | Hôpital Pasteur | Colmar | |
France | Clinique des Cèdres | Cornebarrieu | |
France | Créteil - CHI | Créteil | |
France | Dax - CH | Dax | |
France | Denain - CH | Denain | |
France | Dijon - CAC | Dijon | |
France | Dijon - CHU | Dijon | |
France | Draguignan - CH | Draguignan | |
France | CH de Dreux | Dreux | |
France | Elbeuf - CH | Elbeuf | |
France | Epinal - CH | Epinal | |
France | Ermont - Clinique Claude Bernard | Ermont | |
France | Evreux - CH | Evreux | |
France | Flers - CH | Flers | |
France | CHICAS Site de Gap | Gap | |
France | CHRU Grenoble | Grenoble | |
France | Saint Omer - CHI | Helfaut | |
France | Jonzac - CH | Jonzac | |
France | La Roche Sur Yon - CH | La Roche Sur Yon | |
France | Le Havre - HPE | Le Havre | |
France | Le Mans - Centre Hospitalier | Le Mans | |
France | Le Mans - Clinique Victor Hugo | Le Mans | |
France | CH Dr Schaffner de Lens | Lens | |
France | Liévin - polyclinique de Riaumont | Liévin | |
France | CHU (Hôpital Calmette) - Pneumologie | Lille | |
France | Lille - Hôpital Calmette | Lille | |
France | Limoges - Hôpital du Cluzeau | Limoges | |
France | CH de Longjumeau | Longjumeau | |
France | Lorient - CHBS | Lorient | |
France | Clinique des 4 Pavillons | Lormont | |
France | Clinique Mutualiste Eugène André | Lyon | |
France | HIA Desgenettes | Lyon | |
France | Hôpital de la Croix Rousse | Lyon | |
France | Lyon - Clinique Mutualiste | Lyon | |
France | Lyon - Hôpital Louis Pradel (Pneumologie) | Lyon | |
France | Mantes La Jolie - CH | Mantes La Jolie | |
France | Marseille - CRLCC | Marseille | |
France | Marseille - Hôpital Sainte Marguerite | Marseille | |
France | Polyclinique du Parc | Maubeuge | |
France | Meaux - CH | Meaux | |
France | Metz - Belle Isle | Metz | |
France | Metz - CHR | Metz | |
France | Metz - Clinique Claude Bernard | Metz | |
France | Mont de Marsan - CH | Mont de Marsan | |
France | Montpellier - CHRU | Montpellier | |
France | Montpellier - Clinique Clémentville | Montpellier | |
France | Moulins - CH | Moulins | |
France | Mulhouse - CH | Mulhouse | |
France | CHU Nancy | Nancy | |
France | Nancy - Polyclinique Gentilly | Nancy | |
France | Nanterre - CH | Nanterre | |
France | Hôpital Laënnec - CHU de Nantes | Nantes | |
France | Nantes - Centre René Gauducheau | Nantes | |
France | Narbonne - Polyclinique Le Languedoc | Narbonne | |
France | Neuilly - Hôpital Américain de Paris | Neuilly | |
France | Nevers - CH | Nevers | |
France | Nice - CAC | Nice | |
France | CHU | Nîmes | |
France | Nîmes - Clinique Valdegour | Nîmes | |
France | Orléans - CH | Orléans | |
France | GH Paris Saint-Joseph | Paris | |
France | Hôpital Bichat - Claude - Bernard | Paris | |
France | Hôpital du Val de Grâce | Paris | |
France | Hôpital Européen Georges Pompidou | Paris | |
France | Hôpital Tenon | Paris | |
France | Paris - Curie | Paris | |
France | Paris - hôpital Saint-Antoine | Paris | |
France | Paris - Saint Louis | Paris | |
France | Pau - CH | Pau | |
France | CH de Périgueux | Périgueux | |
France | Perpignan - Centre Catalan d'Oncologie | Perpignan | |
France | Perpignan - Ch | Perpignan | |
France | Lyon Sud | Pierre Bénite | |
France | CHU | Poitiers | |
France | Pontoise - CH | Pontoise | |
France | Reims - CHU | Reims | |
France | Reims - CRLCC | Reims | |
France | Rennes - CHU | Rennes | |
France | CHG de Roanne | Roanne | |
France | Rodez - CH | Rodez | |
France | Roncq - Clinique Saint-Roch | Roncq | |
France | Roubaix - CH | Roubaix | |
France | Centre Frederic Joliot | Rouen | |
France | Rouen - CHU | Rouen | |
France | Saint Brieuc - CHG | Saint Brieuc | |
France | Saint Nazaire - Centre Etienne Dolet | Saint Nazaire | |
France | Saint Priest en Jarez - ICL | Saint Priest en Jarez | |
France | Saint Quentin - CH | Saint Quentin | |
France | Saint-Malo - CH | Saint-Malo | |
France | Saint-Nazaire - CH | Saint-Nazaire | |
France | Saverne - CH | Saverne | |
France | Senlis - CH | Senlis | |
France | Strasbourg - NHC | Strasbourg | |
France | Suresnes - Hopital Foch | Suresnes | |
France | Thonon les bains | Thonon les bains | |
France | Toulon - CHI | Toulon | |
France | Toulon - HIA | Toulon | |
France | Clinique Saint Jean du Languedoc | Toulouse | |
France | Toulouse - CHU Larrey | Toulouse | |
France | Toulouse - Clinique Pasteur | Toulouse | |
France | Tours - CHU | Tours | |
France | Troyes - CH | Troyes | |
France | Valenciennes - Clinique | Valenciennes | |
France | Clinique Mutualiste Les Portes du Sud | Vénissieux | |
France | Verdun - CHG | Verdun | |
France | CHI de la Haute-Saône - Pneumologie | Vesoul | |
France | Vesoul - CHI | Vesoul | |
France | Vienne - CH | Vienne | |
France | Villejuif - Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Intergroupe Francophone de Cancerologie Thoracique |
France,
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca — View Citation
Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J; French Cooperative Thoracic Intergroup (IFCT). Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer. 2020 Feb;140:19-26. doi: 10.1016/j.lungcan.2019.10.013. Epub 2019 Nov 15. — View Citation
Blons H, Oudart JB, Merlio JP, Debieuvre D, de Fraipont F, Audigier-Valette C, Escande F, Hominal S, Bringuier PP, Fraboulet-Moreau S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer. 2021 Jan;151:69-75. doi: 10.1016/j.lungcan.2020.11.008. Epub 2020 Nov 13. — View Citation
Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Lena H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8. — View Citation
Guibert N, Barlesi F, Descourt R, Lena H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazieres J. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. J Thorac Oncol. 2017 Jun;12(6):963-973. doi: 10.1016/j.jtho.2017.02.001. Epub 2017 Feb 9. — View Citation
Kembou Nzale S, Weeks WB, Ouafik L, Rouquette I, Beau-Faller M, Lemoine A, Bringuier PP, Le Coroller Soriano AG, Barlesi F, Ventelou B. Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study. PLoS One. 2020 Jul 1;15(7):e0234387. doi: 10.1371/journal.pone.0234387. eCollection 2020. — View Citation
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404. — View Citation
Mordant P MD, PhD, Brosseau S, Milleron B, Santelmo N, Fraboulet-Moreau S, Besse B, Langlais A, Gossot D, Thomas PA, Pujol JL, Ricordel C, Madelaine J, Lamy R, Audigier-Valette C, Missy P, Blons H, Barlesi F, Westeel V; French Cooperative Thoracic Intergroup (IFCT). Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study. Clin Lung Cancer. 2023 Jan;24(1):1-10. doi: 10.1016/j.cllc.2022.08.013. Epub 2022 Aug 29. — View Citation
Ruppert AM, Beau-Faller M, Debieuvre D, Ouafik L, Westeel V, Rouquette I, Mazieres J, Bringuier PP, Monnet I, Escande F, Ricordel C, Merlio JP, Janicot H, Lemoine A, Foucher P, Poudenx M, Morin F, Langlais A, Souquet PJ, Barlesi F, Wislez M. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. JTO Clin Res Rep. 2020 May 15;1(3):100052. doi: 10.1016/j.jtocrr.2020.100052. eCollection 2020 Sep. — View Citation
Tomasini P, Brosseau S, Mazieres J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F. EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. Eur Respir J. 2017 Aug 10;50(2):1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EGF-R gene mutation in nationwide cohort | Number of patients with EGF-R gene mutation | 1 Year | |
Secondary | K-RAS gene mutation in nationwide cohort | Number of patients with K-RAS gene mutation | 1 year | |
Secondary | EML4-ALK translocation in nationwide cohort | Number of patients with EML4-ALK translocation | 1 year | |
Secondary | BRAF gene mutation in nationwide cohort | Number of patients with BRAF gene mutation | 1 year | |
Secondary | HER2 gene mutation in nationwide cohort | Number of patients with HER2 gene mutation | 1 year | |
Secondary | PI3K gene mutation in nationwide cohort | Number of patients with PI3K gene mutation | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |